Haemonetics (HAE) Cash & Equivalents (2009 - 2026)

Haemonetics has reported Cash & Equivalents for 18 years, with the latest figure at $245.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 19.99% year-over-year to $245.4 million; the trailing twelve-month figure through Mar 2026 stood at $245.4 million (down 19.99% YoY), and the FY2026 full-year result was $245.4 million, down 19.99% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $245.4 million, down from $363.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $363.4 million in Q4 2025, with the low at $178.8 million in Q1 2024.
• Average Cash & Equivalents over 5 years is $274.4 million, with a median of $285.1 million recorded in 2023.
• Year-over-year, Cash & Equivalents tumbled 37.15% in 2024 and soared 71.57% in 2025.
• Tracing HAE's Cash & Equivalents over 5 years: stood at $224.0 million in 2022, then decreased by 13.4% to $194.0 million in 2023, then surged by 65.4% to $320.8 million in 2024, then gained by 13.25% to $363.4 million in 2025, then slumped by 32.45% to $245.4 million in 2026.
• The last three Cash & Equivalents figures came in at $245.4 million (Q1 2026), $363.4 million (Q4 2025), and $296.4 million (Q3 2025), per Business Quant data.

Peer Comparison